ClinicalTrials.gg
CompletedNCT00142493Updated Dec 24, 2015

Effect of Affective Content on Drug Induced Amnesia of Episodic Memory

A Phase 1 interventional study of Propofol and Thiopental Sodium in Memory Losses and Amnesia-Memory Loss, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-24.

Primary conditionAmnesiaRegistry: Memory DisordersReclassifiedWhy we changed it
Registry
Memory Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Amnesia
Why
  1. The study's listed conditions name Amnesia, a narrower term within Memory Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this research is to understand how some of the drugs commonly used in anesthesia impair memory. We are particularly interested in whether the emotion associated with a memory influences how well these drugs are able to block memory. We are studying four commonly used drugs-propofol, thiopental, midazolam, and dexmedetomidine, all of which may have slightly differing effects. We will also study an inactive substance, called a placebo, that should have no effect. The results of this study will provide information that will be useful in understanding how memory works, how these drugs affect memory, and possibly why some people don't have their memory blocked as easily as others.

Read the detailed description

The protocol "Effect of Affective Content on Drug Induced Amnesia of Episodic Memory" investigates the relationship between the ability of affective ('emotional') content to modulate the formation of episodic memory, and the memory impairment ('amnestic') effects of several common intravenous anesthetic drugs. Because memory modulation by affective content appears to be a distinct memory process, the underlying question is whether drugs that impair memory via different mechanisms will have differing effects on memory modulation. Specifically, the objectives are: (1) To study the influence of three GABAergic agents (thiopental, propofol, and midazolam) and one α2-adrenergic agent (dexmedetomidine) on the ability of affective content to modulate the strength of episodic memory; and (2) To study whether the subliminal ('consciously imperceptible') presentation of emotional words can influence memory for visual stimuli shown immediately after the subliminal presentation.

A maximum of eighty volunteers will receive sub-anesthetic doses of one of the four study drugs, or placebo, while performing a visual continuous recognition task ('CRT') of pictures with randomly varying affective load. Drug effect on affective modulation of working and early long-term memory behavior will be examined by analyzing which images are and are not recognized during the CRT. Drug effect on affective modulation of later long-term memory will be examined by analyzing which images are recognized several hours after presentation.

In a second experiment, emotive and non-emotive words are subliminally presented immediately before the presentation of a 'bland' picture. The ability of the subliminally presented word to influence memory will be examined by analyzing which bland images are recognized several hours later.

Three hypotheses are tested:

The memory impairment effected by GABAergic drugs will be stronger for memory of emotively positive images than for memory of emotively negative images

The memory impairment effected by dexmedetomidine will be similar for memory of emotively positive and negative images

Recognition memory for neutral, non-arousing images will be greater if the image is immediately preceded by the subliminal presentation of an emotively arousing word than if it is preceded by an emotively non-arousing word

02

Conditions studied

  • Memory Losses
  • Amnesia-Memory Loss

Browse trials for

Keywords

  • Episodic Memory
  • Amnesia
  • Amnesia, Temporary
03

In context

Amnesia Reclassified

22 studies on the registry are indexed under Amnesia; 2 are open to participants now.

This study's enrollment of 79 is above the median of 62 across 19 interventional studies indexed under Amnesia.

Browse Amnesia studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 327 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Amnesia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Memory Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy normal volunteers, age 18 to 50 years *,who show no evidence of neurologic deficit on questionnaire and physical examination.
  • Females must be non-pregnant as demonstrated using a serum pregnancy test.
  • Right hand dominant.
  • High school education or above.
  • English as native language or equivalent degree of fluency. *Age group selected based on pharmacokinetic models for drug infusion, and norms for standardized memory tests.

Exclusion criteria

Exclusion Criteria:

  • Any evidence of neurologic deficit including seizures, severe head trauma resulting in unconsciousness, or any previously abnormal study of CNS - (e.g. MRI, EEG, etc.)
  • Any deficit in auditory or visual ability.
  • Any history of hypertension (resting BP >150 systolic, >100 diastolic) or taking anti- hypertensive medication or cardiovascular disease.
  • Significant pulmonary, renal, gastrointestinal, or endocrine metabolic disease which in the opinion of the investigator would complicate the goals of this study.
  • Allergy to propofol or eggs.
  • History of acute intermittent porphyria in subject or subject's blood relatives.
  • History of substance abuse
  • Currently taking centrally acting medications (e,g, benzodiazepines or anti depressants)
  • Subjects whose body weight relative to their height exceeds accepted criteria for defining obesity in the general population ( > 30). Excess weight can affect the pharmacodynamics of the drug in the body.
  • Anyone who, in the opinion of the investigators, would be unwilling or unable to tolerate the procedures and/or comply with the task instructions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    1

    Drug: Propofol

  • Experimental
    2

    Drug: Thiopental Sodium

  • Experimental
    3

    Drug: Dexmedetomidine Hydrochloride

  • Experimental
    4

    Drug: Midazolam Hydrochloride

  • Placebo comparator
    5

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. To study the influence of three GABAergic agents (thiopental, propofol, and midazolam) and one α2-adrenergic agent (dexmedetomidine) on the ability of affective content to modulate the strength of episodic memory

    Time frame: over a two day period

Secondary outcomes

  1. To study whether the subliminal ('consciously imperceptible') presentation of emotional words can influence memory for visual stimuli shown immediately after the subliminal presentation

    Time frame: over a two day period

07

Study locations

1 site
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00142493
Responsible party
Sponsor
First posted
Sep 2, 2005
Start date
Sep 2004
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Dec 24, 2015

Study contacts

Kane O. Pryor, M.D.
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Propofol · Thiopental · Dexmedetomidine · Midazolam

Start the discussion